Chiron, GSK Flu Vaccine Availability May Not Be Clear Until August, CDC Says
This article was originally published in The Pink Sheet Daily
Due to uncertainty about the number of vaccine suppliers, the agency has devised an immunization strategy based on three supply scenarios for the 2005-2006 influenza season. The strategy places individuals into tiers based upon their age, health status and contact with persons at high risk.
You may also be interested in...
Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.
Genpharm opens office in New York headed by former Able CEO Robert Mauro.